Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosingLarance, B.; Degenhardt, L.; Lintzeris, N.; Bell, J.; Winstock, A.; Dietze, P.; Mattick, R.; Ali, R.; Horyniak, D.
2008Exposure to opioid maintenance treatment reduces long-term mortalityGibson, A.; Degenhardt, L.; Mattick, R.; Ali, R.; White, J.; O'Brien, S.
2018Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) StudyLarney, S.; Hickman, M.; Fiellin, D.; Dobbins, T.; Nielsen, S.; Jones, N.; Mattick, R.; Ali, R.; Degenhardt, L.
2011Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patientsLarance, B.; Degenhardt, L.; O'Brien, S.; Lintzeris, N.; Winstock, A.; Mattick, R.; Bell, J.; Ali, R.
2009Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulationDegenhardt, L.; Larance, B.; Bell, J.; Winstock, A.; Lintzeris, N.; Ali, R.; Scheuer, N.; Mattick, R.
2016Diversion and injection of buprenorphine-naloxone film two years post-introduction in AustraliaLarance, B.; Mattick, R.; Ali, R.; Lintzeris, N.; Jenkinson, R.; White, N.; Kihas, I.; Cassidy, R.; Degenhardt, L.
2016The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone filmWhite, N.; Ali, R.; Larance, B.; Zador, D.; Mattick, R.; Degenhardt, L.